In a study of 1,685 patients treated with CPA, elevated liver enzymes were seen in 10% of patients at a dosage of 50 mg/day and in 20% of patients at a dosage of greater than 100 mg/day.  A study of 2,506 patients given 18–136 mg/day for less than 48 months per patient reported a rate of %.   In a trial of 89 prostate cancer patients who received high-dose CPA for 4 years, there were elevated liver enzymes in % of the patients.  Yet another study of 105 patients found a hepatotoxicity rate of %, with serious hepatic injury occurring in %.  In 2002, it was reported that there were 18 case reports of CPA-associated hepatitis in the medical literature, with 6 of the cases resulting in death.  In addition, a review article cited a report of 96 instances of hepatotoxicity that were attributed to CPA, and 33 of these instances resulted in death.  Moreover, a 2014 review found that 15 cases specifically of CPA-induced fulminant (sudden-onset and severe) liver failure had been reported to date, with only one of these cases not resulting in death.  As such, the prognosis of CPA-induced liver failure is death. 
This Food Additives Status List, formerly called Appendix A of the Investigations Operations Manual (IOM), organizes additives found in many parts of 21 CFR into one alphabetized list. Additives included are those specified in the regulations promulgated under the FD&C Act, under Sections 401 (Food Standards), and 409 (Food Additives). The Food Additives Status List includes short notations on use limitations for each additive. For complete information on its use limitations, refer to the specific regulation for each substance. New regulations and revisions are published in current issues of the Federal Register as promulgated. Also refer to the Food Ingredient and Packaging inventories in the Foods section of the FDA web site to review several FDA databases of additive categories. For example, the EAFUS list (Everything Added to Food in the United States), is a helpful reference within the limitations described at the beginning of the database.
A larger study with longer follow-up concluded that "use of DMPA during pregnancy or breastfeeding does not adversely affect the long-term growth and development of children". This study also noted that "children with DMPA exposure during pregnancy and lactation had an increased risk of suboptimal growth in height," but that "after adjustment for socioeconomic factors by multiple logistic regression, there was no increased risk of impaired growth among the DMPA-exposed children." The study also noted that effects of DMPA exposure on puberty require further study, as so few children over the age of 10 were observed.